Guggenheim Upgrades Ultragenyx Pharmaceutical to Buy, Announces $50 Price Target
Guggenheim analyst Debjit Chattopadhyay upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Neutral to Buy and announces $50 price target.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $60
Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to In-Line and lowers the price target from $95 to $60.
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: